Home▸Alzheimer's Early Detection Blood Biomarker▸Subjective Cognitive Decline Risk Stratification Simulator

🩸 Subjective Cognitive Decline Risk Stratification Simulator

This simulator assesses and stratifies the risk of subjective cognitive decline in individuals.

Alzheimer's Early Detection Blood Biomarker2DModerate60 FPS
Subjective Cognitive Decline Risk Stratification Simulator ↗ Open standalone

Subjective Cognitive Decline: Complaint Without Measurable Deficit

Placeholder: defining SCD as self-perceived decline with normal objective testing.

  • ~25%: Prevalence 60+ (placeholder population estimate)
  • ~6–8%: Annual conversion (placeholder MCI conversion rate)
  • Normal: Testing sensitivity (placeholder neuropsych result)
  • Memory: Symptom domain (placeholder most common complaint)

Defining the SCD construct

Placeholder text describing SCD diagnostic framework and criteria.

Distinguishing Normal Age-Related Change From Early Neurodegeneration

Placeholder: contrasting benign forgetfulness patterns with early pathological signs.

  • Common: Benign forgetfulness (placeholder normative pattern)
  • Progressive: Red-flag pattern (placeholder concerning trajectory)
  • Key input: Informant report (placeholder corroboration source)
  • Absent: Functional impact (placeholder SCD hallmark)

Normal aging benchmarks

Placeholder text on differentiating normative cognitive aging curves from disease.

Risk Factors That Raise Conversion Likelihood

Placeholder: cataloguing genetic, family, and clinical risk modifiers.

  • Elevated risk: APOE4 carriers (placeholder genetic modifier)
  • 2× risk: Family history (placeholder relative risk estimate)
  • Additive: Vascular factors (placeholder comorbidity effect)
  • Confounder: Depression history (placeholder overlapping symptom)

Stratifying by risk burden

Placeholder text describing cumulative risk factor scoring approach.

When to Consider Biomarker Testing

Placeholder: CSF, amyloid PET, and blood biomarker decision points.

  • Available: CSF Aβ42/tau (placeholder biomarker modality)
  • High cost: Amyloid PET (placeholder access constraint)
  • Emerging: Blood biomarkers (placeholder plasma p-tau assay)
  • Guides use: Pretest probability (placeholder testing threshold)

Biomarker decision criteria

Placeholder text on selecting candidates for biomarker workup.

Choosing Between Monitoring and Immediate Workup

Placeholder: final triage decision balancing risk and patient preference.

  • 12 months: Routine follow-up (placeholder interval for low risk)
  • 6 months: Enhanced monitoring (placeholder interval for moderate risk)
  • Immediate: Urgent workup (placeholder high-risk pathway)
  • Essential: Shared decision (placeholder patient involvement)

Final triage pathway

Placeholder text summarizing the monitoring-versus-workup decision tree.

⚙ Under the hood

This simulator assesses and stratifies the risk of subjective cognitive decline in individuals.

CanvasBiomedicine

2D · HTML5 Canvas 2D · 60 FPS target · runs fully client-side, no install

What did you find?

Add reproduction steps (optional)